Work

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps4580

Authors: James M. G. Larkin, Michael S. Gordon, Fiona Thistlethwaite, Paul D. Nathan, Brian I. Rini, Marcella Martignoni, Michael Shnaidman, Chiara Chiruzzi, Alessandra Di Pietro, Toni K. Choueiri

Institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, HonorHealth, Pinnacle Oncology Hematology, The Christie Hospital, The Christie NHS Foundation Trust, Mount Vernon Cancer Centre, Cleveland Clinic, Pfizer (United States), Dana-Farber Brigham Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2486936960

Cites:

Cited by: 13

Related to: 10